Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Uniting Patient Voices With the Latest Evidence on Novel Targeted Therapies for CLL/SLL

Clinical Thought

Experts answer your questions related to the program, “Beyond CIT: Uniting Patient Voices With the Latest Evidence on Novel Targeted Therapies for CLL/SLL.” This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program. 

Released: May 08, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, and Lilly.

AstraZeneca

BeOne Medicines

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This educational activity is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for individuals with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Support patient engagement in care for CLL/SLL through effective shared decision-making and communication strategies

  • Compare the mechanisms of action and clinical rationales for novel targeted therapies that are approved vs under investigation for management of CLL/SLL

  • Recommend individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with CLL/SLL in alignment with patient preferences, clinical evidence, and expert recommendations

  • Assess the clinical implications of emerging efficacy and safety data for novel targeted and cellular therapies on treatment sequencing in CLL/SLL

  • Apply best practices for biomarker testing before treatment initiation and at disease progression to guide optimal therapy selection and sequencing in patients with CLL/SLL

Disclosure

Primary Author

Catherine C. Coombs, MD: consultant/advisor/speaker: AbbVie, Allogene, AstraZeneca, BeOne, Genentech, Janssen, Johnson & Johnson, Lilly, Octapharma, Pharmacyclics; researcher: AbbVie, BeOne, Carna, Lilly.

Nitin Jain, MD: researcher: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Pharmacyclics, Precision Biosciences, Sana Biotechnology, Takeda, Triarm, Ubix; consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB.

Nicole Lamanna, MD: consultant/advisor: AbbVie, AstraZeneca, BeOne, Lilly/Loxo; researcher (paid to institution): AbbVie, AstraZeneca, BeOne, Lilly/Loxo, Genentech, Genmab, Octapharma, Oncternal.